French real estate investor Icade, has set a price range of €115-135 per share for the upcoming IPO of Icade Sante, its healthcare property business. This values it at up to €6.4bn.
Potential winners of Germany's upcoming elections are pledging to abolish private medical insurance (PKV). The move could spell disaster for the whole healthcare sector: it accounts for 37% of all expenditure.
To date, for-profit assisted living providers have focused more or less exclusively on providing luxury retirement villages to relatively wealthy retirees. This is the case across Europe, but is particularly evident in Germany.
How fast is the world outside America adopting telehealth and digital care in all its forms? Who better to ask than Carlos Nueno, president International for Teladoc Health, which ties with Ping An from China for the title of the world’s largest telehealth operator. So, what new business models are being rolled out and when? And how are countries adopting the new technology?
Domidep, one of the top 10 for-profit care home operators in France by revenue, has expanded in the German market which it entered last year. It has acquired Römergarten Senioren-Residenzen GmbH (Römergarten) which comprises eight care homes providing a total of 660 beds.
Strong rumours reported by HBI back in July that Nordic Capital-backed ophthalmology group Veonet (including Germany's largest operator by revenue Ober Scharrer) would come to market before the autumn have been proven correct. HBI understands the group has launched a process, and a price tag of in excess of €2bn is expected.
Investors in the US are pouring money into dermatology, while EU markets remain far quieter. To find out where and why deals are – and aren’t - happening, we round up the latest news from the sector in Europe, including the UK dermatology consultant-led business Dermatology Partnership, Sweden’s leading dermatology provider Diagnostiskt Centrum Hud, and Dermatologikum Hamburg in Germany.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
